Effectiveness of HPV Vaccine in Thai Adult Women

NCT ID: NCT03763565

Last Updated: 2023-06-05

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 993 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2018-11-01
• Study Completion Date: 2019-07-01

Brief Summary

• Background: The majority of the burden of HPV-related cervical cancer is in developing countries while most of the effectiveness reports of HPV vaccination are currently coming from developed countries. Also, currently many adult women are left without either HPV vaccination or cervical cancer screening. Effectiveness data of currently available HPV vaccines among adult women in developing countries are needed for women and healthcare workers and policy makers to best protect women from cervical cancer.
• Primary Study Objective:

• To determine the effectiveness bivalent and quadrivalent HPV vaccines in reduction of cervical dysplasia (Low-grade Squamous Intraepithelial Lesion or worse; LSIL+) attributable to HPV types 16 or 18 after at least 5 years of vaccination among Thai women vaccinated at their ages 20-45 years with at least one dose of the HPV vaccine
• Secondary Study Objectives:

• To measure the effectiveness of currently available bivalent and quadrivalent HPV vaccines in reducing the prevalence of HPV 16 or 18
• To measure the effectiveness of HPV vaccines in reducing any abnormal Pap smear result (ASC-US+)
• To compare the effectiveness of HPV vaccines according to the number of doses immunized
• To find out risk factor(s) for HPV 16 or 18-related cervical dysplasia in this cohort
• To assess the prevalence of other high-risk HPV types in vaccinated and non-vaccinated group
• To determine direct and/or indirect cost of HPV vaccination
• The hypothesis to be tested: At least one dose of vaccination with bi- or quadri-valent HPV vaccine will reduce the prevalence of LSIL+ attributable to HPV 16/18 by 80% after at least 5 years of vaccination.
• Materials and Methods: This study will be a retrospective matched cohort study. Data is to be collected either by from samples for Pap and HPV test and/or HPV 16/18 genotyping of the recruited participants, or from existing medical records. HPV vaccinated women at their ages 20-45 years (vaccinated group) and women received Pap smear at their ages 20-45 years without vaccination (control group) will be included in the study. Pap smear and HPV test and/or HPV 16/18 typing result of 2 groups will be compared after ≥ 5 years of vaccination or baseline Pap smear. Those who don't have Pap smear results ≥ 5 years after vaccination or ≥ 5 years after the baseline Pap smear will be offered for a Pap smear and HPV 16/18 typing

Conditions

Uterine Cervical Dysplasia; Papillomavirus Vaccines

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Vaccinated group

Thai women who received at least one dose HPV vaccination at least 5 years ago, either by Bivalent or Quadrivalent HPV vaccines when they were 20-45 years old

Bivalent or Quadrivalent HPV vaccines

Intervention Type: BIOLOGICAL

Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years

Control group

Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time

Control group

Intervention Type: OTHER

Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time

Interventions

Bivalent or Quadrivalent HPV vaccines

Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years

Intervention Type: BIOLOGICAL

Control group

Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

(vaccinated group)

• Thai women aged 20-45 years at the time of HPV vaccination
• Received at least 1 dose of bivalent or quadrivalent HPV vaccine at least 5 years ago
• Willing to provide written informed consent and receive Pap smear & HPV genotyping (only for those who need specimen collection for cervical cytology and HPV genotyping result)

(control group)

• Thai women without history of HPV vaccination
• Received Pap smear result at their ages 20-45 years at least 5 years ago
• Willing to provide written informed consent and receive Pap smear & HPV genotyping (only for those who need specimen collection for cervical cytology and HPV genotyping result)

Exclusion Criteria

• Known pregnancy
• History of hysterectomy or excisional treatment of the cervix
• Known increased risk of bleeding
• Not willing to provide written informed consent

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 53 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Vaccine Institute, Thailand

OTHER

Sponsor Role: collaborator

Chulalongkorn University

OTHER

Sponsor Role: collaborator

National Cancer Institute, Thailand

OTHER_GOV

Sponsor Role: collaborator

Bumrungrad International Hospital

OTHER

Sponsor Role: collaborator

Siriraj Hospital

OTHER

Sponsor Role: collaborator

Mahidol University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Punnee Pitisuttithum

Role: STUDY_CHAIR

Mahidol University

Locations

Bumrungrad International Hospital

Bangkok, , Thailand

King Chulalongkorn Memorial Hospital

Bangkok, , Thailand

National Cancer Institute, Thailand

Bangkok, , Thailand

Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University,

Bangkok, , Thailand

Siriraj Hospital, Mahidol University

Bangkok, , Thailand

Countries

Thailand

Other Identifiers

2561.1/13

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

HPV 021

Identifier Type: -

Identifier Source: org_study_id